Hirayama disease is a rare neurological disorder primarily affecting young males. This condition poses diagnostic challenges ...

The χ 2 test, or Fisher's exact test if expected cell counts were less than five ... responses throughout an MI-E protocol in patients with ALS. Treatment failure with MI-E in patients with bulbar ...

As someone deeply immersed in the field of cell therapy, it thrills me to witness the rapid advancements that are pushing the boundaries of patient care further and faster than ever before.

New CAR-T cell therapy shows promise for hard-to-treat cancers Date: March 10, 2025 Source: University of Colorado Anschutz Medical Campus Summary: Researchers have successfully developed a ...

Despite its promise, autologous chimeric antigen receptor T-cell (CAR T-cell) therapy faces several challenges, including limited accessibility, high costs and manufacturing bottlenecks. Allogeneic ...

"When you look back, it's easy to see how revolutionary CAR-T cells have been. But, for many patients this therapy isn't enough. And stepping back you realize that we have been driving these CAR-T ...

With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech Pharmaceuticals is on the verge of making its commercial debut. The FDA last week ...

An FDA advisory committee has voted by a huge margin that BrainStorm’s stem cell therapy for amyotrophic lateral sclerosis (ALS) – NurOwn – does not have enough data to support its approval.

Such neurons could be used to treat spinal cord injuries or diseases such as Amyotrophic Lateral Sclerosis (ALS ... step toward developing these cells as a therapy, the researchers showed ...